key: cord-1024839-09au87o9
authors: Nishida, T.; Iwahashi, H.; Yamauchi, K.; Kinoshita, N.; Okauchi, Y.; Suzuki, N.; Inada, M.; Abe, K.
title: Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan
date: 2020-09-11
journal: nan
DOI: 10.1101/2020.09.10.20191866
sha: da0a74c30dc9762d7120d1867e948ae5c2e3d0a1
doc_id: 1024839
cord_uid: 09au87o9

Background: The subclinical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rate in hospitals during the pandemic remains unclear. To evaluate the effectiveness of our hospital's current nosocomial infection control, we conducted a serological survey of the anti-SARS-CoV-2 antibody (immunoglobulin G) among the staff of our hospital, which is treating coronavirus disease 2019 (COVID-19) patients. Methods: The study design was cross-sectional. We measured anti-SARS-CoV-2 immunoglobulin G in the participants using a laboratory-based quantitative test (Abbott immunoassay), which has a sensitivity and specificity of 100% and 99.6%, respectively. To investigate the factors associated with seropositivity, we also obtained some information from the participants with an anonymous questionnaire. Results: We invited 1133 staff members in our hospital, and 925 (82%) participated. The mean age of the participants was 40.0{+/-}11.8 years, and most were women (80.0%). According to job title, there were 149 medical doctors or dentists (16.0%), 489 nurses (52.9%), 140 medical technologists (14.2%), 49 healthcare providers (5.3%), and 98 administrative staff (10.5%). The overall prevalence of seropositivity for anti-SARS-CoV-2 IgG was 0.43% (4/925), which was similar to the control seroprevalence of 0.54% (16/2970)) in the general population in Osaka during the same period according to a government survey conducted with the same assay. Seropositive rates did not significantly differ according to job title, exposure to suspected or confirmed COVID-19 patients, or any other investigated factors. Conclusion: The subclinical SARS-CoV-2 infection rate in our hospital was not higher than that in the general population under our nosocomial infection control measures.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020 September 11, . . https://doi.org/10.1101 September 11, /2020 doi: medRxiv preprint We invited all our hospital staff planning to undergo a regular health check-up to 1 0 7 participate in this study via the intranet at our hospital. The following individuals were 1 0 8 excluded from the study: those who refused to take part in this study; those who did not have enough extra blood drawn to undergo antibody testing; and those who were not 1 1 0 identified because they mistyped their personal ten-digit identification code. Finally, in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 /2020 To investigate the risk factors for seropositivity, we asked participants to answer form. The details of this questionnaire are shown in Table 1 .

The present study was conducted in accordance with the principles of the 1 1 9

Declaration of Helsinki, and approval was obtained from the Institutional Review Board 1 2 0 of Toyonaka Municipal Hospital (No. 2020-05-08). We obtained written informed 1 2 1 consent from participants prior to the study. All samples were collected and stored at -20°C until use. IgG antibodies against 1 2 5 SARS-CoV-2 were detected using a laboratory-based quantitative assay (Abbott . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 /2020 instructions. The Food and Drug Administration (FDA) has not fully authorized any 1 3 1 COVID-19 test, but this kit has been authorized for emergency use 6 . The primary outcome was the rate of seropositivity for anti-SARS-CoV-2 IgG. The key secondary outcomes were the rate of seropositivity for anti-SARS-CoV-2 IgG The means ± standard deviations are reported for continuous variables. Categorical variables are summarized as frequencies (percentages) with 95% confidence 1 4 4 intervals (CIs) for the rate of seropositivity. A t-test was used to compare age. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. were performed with JMP statistical software (ver. 14.3, SAS Institute, Inc., Cary, NC, CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint 1 2

Of the 1133 hospital staff who had planned to undergo an annual health check-up 1 5 2 at our hospital in June 2020, 926 agreed to participate in the present study. Finally, 925 1 5 3 (81.6%) were tested for anti-SARS-CoV-2 IgG. One person was not tested due to an 1 5 4 inadequate amount of serum. There was a female predominance (80.0%). The mean age administrative staff members (10.5%) ( Table 2) . Overall, 4 participants were positive for anti-SARS-CoV-2 IgG (0.43%, 95% 1 5 9 confidential interval (CI); 0.17-1.1%). Seropositive participants were significantly older 1 6 0 than seronegative participants (52.8±6.8 vs. 40.0±11.8, P=0.0309), but sex was not 1 6 1 significantly different (males: 50% (2/4) vs. 19.9% (183/921), P=0.1805). Table 2 1 6 2 shows the prevalence of seropositivity for anti-SARS-CoV-2 IgG stratified by the 1 6 3 participants' characteristics. Doctors and dentists had a slightly higher rate of seropositivity (1.3%) than people in other jobs, but there was no significant difference 1 6 5 in rates among people with different job titles. No hospital staff responded that they had 1 6 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint 13 been diagnosed with COVID-19 since February 2020. Table 3 shows the prevalence of seropositivity for anti-SARS-CoV-2 IgG based 1 6 8 on exposure to patients with COVID-19. Subjects who had experienced common cold 1 6 9 symptoms from February 2020 to June 2020 had a slightly higher seropositivity rate, 1 7 0 but the difference was not significant. There were no significant differences in rates . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint patients with confirmed COVID-19 7 . We also performed a total of 415 nasopharyngeal This study showed that the prevalence of seropositivity for SARS-CoV-2 IgG as 1 8 3 evaluated with a laboratory-based quantitative test (Abbott immunoassay) was 0.43% in 1 8 4 our hospital. Considering that the sensitivity of this assay is 100%, the true-positive rate 1 8 5 in our hospital should be less than 0.43%. In addition, 0.43% is similar to or less than 1 8 6 the proportion (0.54% (16/2970)) identified by the same assay in the general population in Osaka during the same period (7). The results of this study demonstrated that our . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10. 1101 /2020 Until now, the percentage of the staff of a general hospital with subclinical 1 9 0 SARS-CoV-2 infections has remained unclear. Although it may change according to the 1 9 1 epidemic condition in the region in which the hospital is located or the number of implemented by the hospital. Our hospital is located in the pandemic region in Japan, 1 9 5 however, the situation regarding the pandemic is much more severe in China than in 1 9 6 Japan 8 . The strength of the present study was that we could compare the results with 1 9 7 large-scale control data in the same region. Osaka is the second-largest metropolitan 1 9 8 region in Japan, with a population of 2.67 million. As of July 21, 2020, there was a total 1 9 9 of 2541 confirmed cases COVID-19 and 84 related deaths in the Osaka region. including Osaka, during the same period and using the same immunoassay from Abbott (4/1971) in Tokyo, and 0.11% (3/3009) in Miyagi 9 . Therefore, we can compare this 2 0 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. successfully managed to avoid hospital-acquired infections. Softbank Group survey also consisted of 5850 subjects with ties to a hospital, and 105 2 1 5 were positive, for a seropositive rate of 1.79% 10 . They concluded that health care 2 1 6 providers are generally more likely than the general public to be positive for 2 1 7 anti-SARS-CoV-2 antibodies 10 . However, the positive rate of 0.43% in our hospital 2 1 8 was similar to that in the general population in Osaka. These data also suggested that . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint

We obtained some information about the participants' backgrounds, their 2 2 2 involvement with general patients, their involvement with patients with suspected or 2 2 3 confirmed cases of COVID-19, and their general condition. We attempted to investigate 2 2 4 risk factors associated with seropositivity, but the low positive rate made this impossible. Future studies with a longer period will be needed.

This study has several limitations. First, we could not survey all the staff in our 2 2 7 hospital; thus, the prevalence found in this study may not be exact. However, more than 2 2 8 80% of the hospital staff in our hospital, including staff in all jobs, were involved in the 2 2 9 present study. We believe the result obtained from this study is very close to the exact . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint 1 8 serological test, we can assume at the very least that the subclinical SARS-CoV-2 2 3 7 infection rate is less than 0.43% in our hospital.

In conclusion, we found that the subclinical SARS-CoV-2 infection rate in our 2 3 9 hospital, which treats COVID-19 patients during the pandemic in Japan, is not higher 2 4 0 than that in the general population in the same area during the same period. Timely CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. We have no conflicts of interest to declare. We thank Issuikai and Hokenkagakunishinihon for collecting and storing the serum . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint No . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20191866 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 /2020 

Clinical characteristics of 54 medical staff with

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted September 11, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 /2020